Abstract:PurposeColon cancer-associated transcript 1 (CCAT1) was identified as an oncogenic long non-coding RNA (lncRNA) in a variety of cancers. However, there was a lack of understanding of the mechanism by which CCAT1 conferred cisplatin (also known as DDP) resistance in ovarian cancer cells.Materials and MethodsCell viability of A2780, SKOV3, A2780/DDP, and SKOV3/DDP cells upon cisplatin treatment was monitored by MTT assay. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) detected the expression levels of CCAT1 and miR-454. The effect of sh-CCAT1 on cisplatin response was investigated in xenografts study. Bioinformatic analysis, luciferase reporter assay and qRT-PCR were conducted to validate the direct interaction among CCAT1, miR-454, and survivin. Apoptosis was determined by flow cytometry after dual staining of Annexin-V-FITC/propidium iodide, and the expression of apoptosis-related proteins Bcl-2, Bax and survivin were detected by qRT-PCR and Western blotting. Xenograft study was conducted to monitor in vivo tumor formation.ResultsCCAT1 was highly expressed in cisplatin-resistant ovarian cancer cell line A2780/DDP and SKOV3/DDP. Knockdown of CCAT1 restored sensitivity to cisplatin in vitro and in vivo . Our data revealed that silencing of CCAT1 promoted cisplatin-induced apoptosis via modulating the expression of pro- or anti-apoptotic proteins Bax, Bcl-2, and survivin. CCAT1 directly interacted with miR-454, and miR-454 overexpression potentiated cisplatin-induced apoptosis. Survivin was identified as a functional target of miR-454, restoration of survivin attenuated the effect of miR-454 on cisplatin response. In addition, miR-454 inhibitor or overexpression of survivin was found to abolish sh-CCAT1–induced apoptosis upon cisplatin treatment.ConclusionCCAT1/miR-454/survivin axis conferred cisplatin resistance in ovarian cancer cells.

Proapoptotic Protein Smac Mediates Apoptosis in Cisplatin-Resistant Ovarian Cancer Cells when Treated with the Anti-Tumor Agent AT101.

Cisplatin Induces Apoptosis of Hepatocellular Carcinoma LM3 Cells Via Down-Regulation of XIAP.

GANT61 Elevates Chemosensitivity to Cisplatin Through Regulating the Hedgehog, AMPK and Camp Pathways in Ovarian Cancer

Akt-Mediated Cisplatin Resistance in Ovarian Cancer: Modulation of p53 Action on Caspase-Dependent Mitochondrial Death Pathway

Noxa-Induced Alterations In The Bax/Smac Axis Enhance Sensitivity Of Ovarian Cancer Cells To Cisplatin

The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis

Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells

Overexpression of Smac Promotes Cisplatin-Induced Apoptosis by Activating Caspase-3 and Caspase-9 in Lung Cancer A549 Cells

Proteasome Inhibitor Ysy01a Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells

The P53 Upregulated Modulator of Apoptosis (PUMA) Chemosensitizes Intrinsically Resistant Ovarian Cancer Cells to Cisplatin by Lowering the Threshold Set by Bcl-x(L) and Mcl-1.

Pharmacological Inhibition of BAD Ser99 Phosphorylation Enhances the Efficacy of Cisplatin in Ovarian Cancer by Inhibition of Cancer Stem Cell-like Behavior

TAT‑fused IP3R‑derived Peptide Enhances Cisplatin Sensitivity of Ovarian Cancer Cells by Increasing ER Ca2+ Release

[Relationship Between Expression of Apoptosis-Associated Proteins and Caspase-3 Activity in Cisplatin-Resistant Human Ovarian Cancer Cell Line].

Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving

AT101 Exerts a Synergetic Efficacy in Gastric Cancer Patients with 5-FU Based Treatment Through Promoting Apoptosis and Autophagy.

Molecular Mechanism of Apoptosis in Cisplatin-Resistant Human Ovarian Cancer Cell Lines Promoted by Topotecan

AT-101 inhibits hedgehog pathway activity and cancer growth

A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors

miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells